Organon & Co. OGN

Organon & Co. es una empresa farmacéutica global basada en la ciencia. La empresa se dedica al desarrollo y entrega de soluciones de salud a través de un portafolio de terapias con receta en salud de la mujer, biosimilares y marcas establecidas. Su portafolio de salud de la mujer incluye Nexplanon o Implanon NXT, que es un anticonceptivo reversible de acción prolongada patentado. Sus segmentos operativos incluyen el segmento de Productos de Organon. El segmento de Productos de Organon se dedica al desarrollo y entrega de soluciones de salud a través de su portafolio de terapias con receta en salud de la mujer, biosimilares y marcas establecidas. El portafolio del segmento de productos de la empresa incluye: Salud de la Mujer, Biosimilares y Marcas Establecidas. Salud de la Mujer contiene marcas anticonceptivas y de fertilidad, como Nexplanon o Implanon NXT, NuvaRing y elonva. El portafolio de Biosimilares de la empresa consta de tres productos de inmunología: Brenzys, Renflexis y Hadlima; y dos productos de oncología: Ontruzant y Aybintio.

Con 73 acciones de OGN (USD 1.001,19) habrías recibido USD 5,84 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

  Organon (OGN), a pharmaceutical company, is being closely watched by investors. The stock has underperformed the S&P 500 over the past month (-0.4% vs +0.6%). Earnings estimates remain unchanged with expected EPS of $0.91 for the current quarter (down 9.9% YoY) and $3.37 for the fiscal year (down 7.9% YoY). Revenue is expected to decline slightly. The company received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. However, it is trading at a discount to peers based on valuation metrics.

  

• GlobeNewswire Inc. 22 jun

  BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

  Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

  

• GlobeNewswire Inc. 16 jun

  Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

  Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

  

• GlobeNewswire Inc. 16 jun

  BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG), Organon & Co. (NYSE – OGN)

  Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).

  

• GlobeNewswire Inc. 9 jun

  Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

  Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.